IRIS
VICENTI, ILARIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.594
EU - Europa 5.485
AS - Asia 2.491
SA - Sud America 518
AF - Africa 48
OC - Oceania 5
Continente sconosciuto - Info sul continente non disponibili 1
Totale 14.142
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.508
RU - Federazione Russa 1.398
GB - Regno Unito 1.001
SG - Singapore 883
IT - Italia 771
CN - Cina 739
IE - Irlanda 737
BR - Brasile 450
DE - Germania 399
SE - Svezia 365
HK - Hong Kong 288
FR - Francia 224
FI - Finlandia 163
UA - Ucraina 162
VN - Vietnam 148
KR - Corea 141
IN - India 110
ES - Italia 72
CA - Canada 40
BE - Belgio 33
JP - Giappone 31
MX - Messico 31
PL - Polonia 30
AT - Austria 29
BD - Bangladesh 28
AR - Argentina 27
TR - Turchia 26
NL - Olanda 23
ZA - Sudafrica 19
CZ - Repubblica Ceca 16
IQ - Iraq 16
IR - Iran 12
LT - Lituania 12
EC - Ecuador 10
CI - Costa d'Avorio 9
AE - Emirati Arabi Uniti 8
ID - Indonesia 8
EG - Egitto 7
GR - Grecia 7
PY - Paraguay 7
UZ - Uzbekistan 7
AZ - Azerbaigian 6
CO - Colombia 6
DK - Danimarca 6
EE - Estonia 6
LV - Lettonia 6
MA - Marocco 5
PK - Pakistan 5
CL - Cile 4
DO - Repubblica Dominicana 4
JM - Giamaica 4
NP - Nepal 4
PA - Panama 4
PE - Perù 4
VE - Venezuela 4
AU - Australia 3
BG - Bulgaria 3
BO - Bolivia 3
GE - Georgia 3
IL - Israele 3
KZ - Kazakistan 3
LK - Sri Lanka 3
PT - Portogallo 3
SK - Slovacchia (Repubblica Slovacca) 3
TW - Taiwan 3
BA - Bosnia-Erzegovina 2
BW - Botswana 2
CH - Svizzera 2
CY - Cipro 2
GY - Guiana 2
JO - Giordania 2
KG - Kirghizistan 2
LU - Lussemburgo 2
RO - Romania 2
RS - Serbia 2
TH - Thailandia 2
TN - Tunisia 2
AL - Albania 1
AM - Armenia 1
BH - Bahrain 1
BY - Bielorussia 1
ET - Etiopia 1
EU - Europa 1
HN - Honduras 1
HU - Ungheria 1
IM - Isola di Man 1
KE - Kenya 1
MD - Moldavia 1
MY - Malesia 1
NC - Nuova Caledonia 1
NG - Nigeria 1
NI - Nicaragua 1
NO - Norvegia 1
PH - Filippine 1
PS - Palestinian Territory 1
SA - Arabia Saudita 1
SN - Senegal 1
TM - Turkmenistan 1
TT - Trinidad e Tobago 1
TV - Tuvalu 1
Totale 14.140
Salva come PNG Salva come JPEG
Città #
Southend 848
Dallas 799
Dublin 730
Fairfield 529
Singapore 521
Chandler 443
Ashburn 398
Moscow 375
Santa Clara 352
Hong Kong 280
Siena 233
Woodbridge 225
Munich 222
Beijing 219
Ann Arbor 216
Seattle 216
Houston 197
Cambridge 187
Wilmington 167
Hefei 148
Seoul 137
Jacksonville 127
Princeton 117
New York 112
Los Angeles 104
Helsinki 84
Milan 68
Rome 64
Bengaluru 49
Boardman 44
Ho Chi Minh City 44
Málaga 44
San Diego 41
Shanghai 40
San Mateo 38
São Paulo 37
Buffalo 34
The Dalles 32
Brussels 31
Florence 31
Redondo Beach 31
Turku 31
Nanjing 29
Portsmouth 29
Hanoi 28
London 25
Warsaw 25
Nuremberg 24
Tokyo 24
Chicago 23
Council Bluffs 22
Dong Ket 22
Dearborn 21
Lappeenranta 21
Lauterbourg 20
Denver 19
Vienna 19
Brooklyn 17
Columbus 17
Düsseldorf 16
Frankfurt am Main 16
Fremont 16
Johannesburg 16
Mexico City 16
Montreal 16
Nanchang 16
Stockholm 16
Atlanta 15
Chennai 14
Guangzhou 14
Poplar 14
Rio de Janeiro 14
San Francisco 14
Toronto 14
Changsha 13
Phoenix 12
Manchester 11
Redwood City 11
Belo Horizonte 10
Brescia 10
Norwalk 10
Orem 10
Abidjan 9
Brasília 9
Kunming 9
Mumbai 9
Newark 9
Perugia 9
Tianjin 9
Jiaxing 8
Menlo Park 8
Naples 8
Roccagorga 8
Ankara 7
Brno 7
Da Nang 7
Messina 7
Paris 7
San Jose 7
Washington 7
Totale 9.488
Salva come PNG Salva come JPEG
Nome #
Prevalence of acquired resistance mutations in a large cohort of perinatally infected HIV-1 patients 306
Agreement between an in-house replication competent and a reference replication defective recombinant virus assay for measuring phenotypic resistance to HIV-1 protease, reverse transcriptase, and integrase inhibitors 299
The HIV-1 reverse transcriptase E138A natural polymorphism decreases the genetic barrier to resistance to etravirine in vitro 277
Comparable in vitro activity of second-generation HIV-1 integrase strand transfer inhibitors (INSTIs) on HIV-1 clinical isolates with INSTI resistance mutations 277
Maraviroc as a potential HIV-1 latency-reversing agent in cell line models and ex vivo CD4 T cells 257
Changing patterns in HIV-1 non-B clade prevalence and diversity in Italy over three decades 252
Analysis of genetic and viral determinants of HBsAg levels in patients with chronic HBV infection 247
Stability of unfrozen whole blood DNA for remote genotypic analysis of HIV-1 coreceptor tropism 241
Prevalence and determinants of resistance mutations in HIV-1-infected patients exposed to integrase inhibitors in a large Italian cohort 238
Development of an internally controlled quantitative PCR to measure total cell-associated HIV-1 DNA in blood 236
Performance of Geno2Pheno[coreceptor] to infer coreceptor use in human immunodeficiency virus type 1 (HIV-1) subtype A 234
Three-class-resistant human immunodeficiency virus type 1 variant in a drug-naive heterosexual couple 230
Low-cost simultaneous detection of CCR5-delta32 and HLA-B*5701 alleles in human immunodeficiency virus type 1 infected patients by selective multiplex endpoint PCR 229
Comparative analysis of different cell systems for Zika virus (ZIKV) propagation and evaluation of anti-ZIKV compounds in vitro 225
Detection of residual human immunodeficiency virus type 1 reverse transcriptase K103N minority species in plasma RNA and peripheral blood mononuclear cell DNA following discontinuation of non-nucleoside therapy 224
Near Full-Length Sequence Analysis of HIV Type 1 BF Recombinants from Italy 218
Evaluation of sofosbuvir activity and resistance profile against West Nile virus in vitro 218
The HIV-1 integrase E157Q polymorphism per se does not alter susceptibility to raltegravir and dolutegravir in vitro 217
In vitro cross-resistance to doravirine in a panel of HIV-1 clones harbouring multiple NNRTI resistance mutations 216
Natural variability in the HR-1 and HR-2 domains of HIV type 1 gp41 from different clades circulating in Italy 208
Cellular and Molecular Mechanisms of In Vivo and In Vitro SARS-CoV-2 Infection: A Lesson from Human Sperm 206
Evidence of differential selection of HIV-1 variants carrying drug resistant mutations in seroconverters 201
Evaluation of HIV-1 integrase resistance emergence and evolution in patients treated with integrase inhibitors 200
Exploring the implication of DDX3X in DENV infection: discovery of the first-in-class DDX3X fluorescent inhibitor 199
Evaluation of a commercial real-time PCR kit for the detection of the Q80K polymorphism in plasma from HCV genotype 1a infected patients 189
Bithiazole Inhibitors of Phosphatidylinositol 4-Kinase (PI4KIIIβ) as Broad-Spectrum Antivirals Blocking the Replication of SARS-CoV-2, Zika Virus and Human Rhinoviruses 186
Naturally occurring hepatitis C virus (HCV) NS3/4A protease inhibitor resistance-related mutations in HCV genotype 1-infected subjects in Italy 184
Distribution of different HBV DNA forms in plasma and peripheral blood mononuclear cells (PBMCs) of chronically infected patients with low or undetectable HBV plasma viremia 179
Hepatitis B virus vaccination in HIV-1-infected young adults: A tool to reduce the size of HIV-1 reservoirs? 178
Development of a Cell-Based Immunodetection Assay for Simultaneous Screening of Antiviral Compounds Inhibiting Zika and Dengue Virus Replication. 178
System-oriented optimization of multi-target 2,6-diaminopurine derivatives: Easily accessible broad-spectrum antivirals active against flaviviruses, influenza virus and SARS-CoV-2 171
Impact of remote vs. local sampling on sensitivity of genotypic antiretroviral resistance testing 167
A Comparison of Sanger Sequencing and Amplicon-Based Next Generation Sequencing Approaches for the Detection of HIV-1 Drug Resistance Mutations 166
Dynamics of total and intact HIV-1 DNA in virologically suppressed patients switching to DTG- or ATV-based dual therapy 165
Surveillance for severe acute respiratory infections among hospitalized subjects from 2015/2016 to 2019/2020 seasons in Tuscany, Italy 165
Impact of circulating resistance-associated mutations on HIV pre-exposure prophylaxis (PrEP) efficacy: Modeling from antiretroviral resistance cohort analysis (ARCA) national database 164
Piperazine-derived small molecules as potential Flaviviridae NS3 protease inhibitors. In vitro antiviral activity evaluation against Zika and Dengue viruses 157
Decreased neutralization of the Eta SARS-CoV-2 variant by sera of previously infected and uninfected vaccinated individuals 157
Serendipitous identification of azine anticancer agents using a privileged scaffold morphing strategy 156
Unique domain for a unique target: selective inhibitors of host cell DDX3X to fight emerging viruses 155
Efficacy of Licensed Monoclonal Antibodies and Antiviral Agents against the SARS-CoV-2 Omicron Sublineages BA.1 and BA.2 154
Faster decay of neutralizing antibodies in never infected than previously infected healthcare workers three months after the second BNT162b2 mRNA COVID-19 vaccine dose 153
Rules-based HIV-1 genotypic resistance interpretation systems predict 8-week and 24-week virological antiretroviral treatment outcome and benefit from drug potency weighting 152
Molecular Tracing of SARS-CoV-2 in Italy in the First Three Months of the Epidemic 150
Integrase strand transfer inhibitor-based regimen is related with a limited HIV-1 V3 loop evolution in clinical practice 149
Pretreatment HIV drug resistance and treatment failure in non-Italian HIV-1-infected patients enrolled in ARCA 145
Targeting the RdRp of Emerging RNA Viruses: The Structure-Based Drug Design Challenge 145
External quality assessment of HIV-1 DNA quantification assays used in the clinical setting in Italy 140
Comparable Post-Vaccination Decay of Neutralizing Antibody Response to Wild-Type and Delta SARS-CoV-2 Variant in Healthcare Workers Recovered from Mild or Asymptomatic Infection 139
Use of peripheral blood DNA for genotypic antiretroviral resistance testing in drug-naïve HIV-infected subjects. 137
SARS-CoV-2 and influenza virus coinfections in the Tuscan population during the 2021/2022 influenza season 135
SARS-CoV-2 Neutralizing Antibodies to B.1 and to BA.5 Variant after Booster Dose of BNT162b2 Vaccine in HIV Patients COVID-Naïve and on Successful Antiretroviral Therapy 134
Zika virus in west africa: A seroepidemiological study between 2007 and 2012 133
SARS-CoV-2 RNA dependent RNA polymerase as a therapeutic target for COVID-19 132
Privileged Scaffold Decoration for the Identification of the First Trisubstituted Triazine with Anti-SARS-CoV-2 Activity 129
Circulating SARS-CoV-2 variants in Italy, October 2020-March 2021 128
Nucleoside Derivatives of 2,6-Diaminopurine Antivirals: Base-Modified Nucleosides with Broad-Spectrum Antimicrobial Properties 127
Neutralizing activity of African lineage Zika virus immune sera towards Asian lineage 126
No impact of previous NRTIs resistance in HIV positive patients switched to DTG+2NRTIs under virological control: Time of viral suppression makes the difference 126
Synthesis and biological investigation of peptidomimetic SARS‐CoV‐2 main protease inhibitors bearing quinoline‐based heterocycles at P3 124
Combined doravirine and islatravir cooperate to inhibit NRTI and NNRTI resistant HIV-1 in vitro 122
Neutralizing antibodies response to novel SARS-CoV-2 omicron sublineages in long-term care facility residents after the fourth dose of monovalent BNT162b2 COVID-19 vaccination 121
null 121
Impact of pre-existent drug resistance on virological efficacy of single-tablet regimens in people living with HIV 120
BNT162b2 SARS-CoV-2 vaccination elicits high titers of neutralizing antibodies to both b.1 and p.1 variants in previously infected and uninfected subjects 120
The second dose of the BNT162b2 mRNA vaccine does not boost SARS-CoV-2 neutralizing antibody response in previously infected subjects 119
Sofosbuvir selects for drug-resistant amino acid variants in the zika virus RNA-dependent RNA-polymerase complex in vitro 119
In vitro anti-sars-cov-2 activity of selected metal compounds and potential molecular basis for their actions based on computational study 119
Frequent Detection of Antiretroviral Drug Resistance in HIV-1-Infected Orphaned Children Followed at a Donor-Funded Rural Pediatric Clinic in Dodoma, Tanzania 116
In vitro susceptibility of HIV-1 CRF02_AG to temsavir, the active compound of the attachment inhibitor fostemsavir 115
In Vitro Combinatorial Activity of Direct Acting Antivirals and Monoclonal Antibodies against the Ancestral B.1 and BQ.1.1 SARS-CoV-2 Viral Variants 115
null 114
Role of phenotypic investigation in the era of routine genotypic HIV-1 drug resistance testing 114
Comparison of Different HIV-1 Resistance Interpretation Tools for Next-Generation Sequencing in Italy 112
Long-Term Longitudinal Analysis of Neutralizing Antibody Response to Three Vaccine Doses in a Real-Life Setting of Previously SARS-CoV-2 Infected Healthcare Workers: A Model for Predicting Response to Further Vaccine Doses 112
Optimization of potent, broad-spectrum, and specific anti-influenza compounds targeting RNA polymerase PA-PB1 heterodimerization 108
Single-dose BNT162b2 mRNA COVID-19 vaccine significantly boosts neutralizing antibody response in health care workers recovering from asymptomatic or mild natural SARS-CoV-2 infection 105
SARS-CoV2 infection in human testis and sperm: in vivo and in vitro studies 104
SARS-CoV-2 infection of human ovarian cells: an in vitro model for the detection of the virus entry into the host cells 102
Serum neutralizing activity against b.1.1.7, b.1.351, and p.1 sars-cov-2 variants of concern in hospitalized covid-19 patients 99
Time Course of Neutralizing Antibody in Health Care Workers With Mild or Asymptomatic COVID-19 Infection 95
SARS-CoV-2 Infection of Human Ovarian Cells: A Potential Negative Impact on Female Fertility 94
Efficacy of Dolutegravir versus Darunavir in Antiretroviral First-Line Regimens According to Resistance Mutations and Viral Subtype 91
Impact of SARS-CoV-2 omicron and delta sub-lineage AY.4.2 variant on neutralization by sera of patients treated with different licensed monoclonal antibodies 88
HIV-1 Integrase Inhibition Activity by Spiroketals Derived from Plagius flosculosus, an Endemic Plant of Sardinia (Italy) and Corsica (France) 87
Switching the three-component Biginelli-like reaction conditions for the regioselective synthesis of new 2-amino[1,2,4]triazolo[1,5-a]pyrimidines 87
Genomic epidemiology of the main SARS-CoV-2 variants in Italy between summer 2020 and winter 2021 77
Two distinct hepatitis C virus genotype 1a clades have different geographical distribution and association with natural resistance to NS3 protease inhibitors 74
Incorporating temporal dynamics of mutations to enhance the prediction capability of antiretroviral therapy’s outcome for HIV-1 61
Phylogeography and genomic epidemiology of SARS-CoV-2 in Italy and Europe with newly characterized Italian genomes between February-June 2020 56
Analysis of the SARS-CoV-2 inactivation mechanism using violet-blue light (405 nm) 52
The Combination of Molnupiravir with Nirmatrelvir or GC376 Has a Synergic Role in the Inhibition of SARS-CoV-2 Replication In Vitro 50
Zika Virus Epidemiology in Selected West African Countries between 2007 and 2012 40
null 32
Pre and Post-Monoclonal Infusion Neutralizing Activity in a Subgroup of Patients Treated in the Presence of two SARS-CoV-2 Dominant Variant of Concern (VOCs) and an Ongoing Vaccination. Overall Clinical Efficacy of Two Monoclonal Antibodies Association in Umbria 23
null 14
null 12
Harnessing prebiotic formamide chemistry: a novel platform for antiviral exploration 9
Totale 14.449
Salva come PNG Salva come JPEG
Categoria #
all - tutte 50.155
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 50.155
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021762 0 0 0 0 0 138 114 141 112 103 69 85
2021/20221.238 69 136 92 161 66 65 71 71 69 109 110 219
2022/20231.426 78 204 166 164 126 270 69 100 97 61 63 28
2023/20241.197 38 36 101 77 21 307 408 35 8 26 34 106
2024/20252.978 67 99 377 183 288 231 110 207 319 158 295 644
2025/20264.453 476 832 779 899 1.411 56 0 0 0 0 0 0
Totale 14.449